A thought-provoking discussion between Whitehead Institute Director and President Ruth Lehmann and Cori Bargmann, Torsten N. Wiesel Professor and Head of the Laboratory of Neural Circuits and Behavior, The Rockefeller University.
Whitehead Institute Director Ruth Lehmann and award-winning science writer Carl Zimmer discuss why broad science literacy is important, especially in the face of climate change and the COVID-19 pandemic.
David Page discusses differences between XX and XY cells across the body, likely contributing to differences between males and females in the incidence, severity, and progression of diseases that collectively affect all organ systems.
Ruth Lehmann and Wellesley College President Paula Johnson discuss how to improve healthcare for women and increase opportunities for women as leaders in biomedicine and higher education.
Whitehead Institute Member Sebastian Lourido discusses his lab's latest findings on how parasites establish long-lived chronic infections in their hosts.
A conversation between Ruth Lehmann, Director, Whitehead Institute, and scientist and inventor, Robert Langer, MIT Institute Professor, on how chemical and biological engineering will impact human health.
An interactive discussion with Dr. Jeremy Yoder, assistant professor in the Department of Biology at California State University, Northridge
We continue the Institute’s Diversity, Equity and Inclusion Seminar Series with Sandra Yamate, CEO of the Institute for Inclusion in the Legal Profession.
In this talk, Rudolf Jaenisch will summarize the stages of SARS-CoV-2 infection and highlight some puzzling observations.
This webinar explains some of the non-genomic mechanisms for the transfer of maternal information to the next generation — and how that information uniquely shapes inheritance.
Join Ruth Lehmann, Director, Whitehead Institute as she speaks with Jennifer Doudna, University of California, Berkeley professor and Nobel Laureate, about her role in the development of CRISPR-Cas9. They will discuss the potential applications of this world-changing genetic technology, the societal and ethical implications of gene editing as well as current research projects, collaborations, and new advances in biology.
The Institute’s Diversity, Equity & Inclusion (DE&I) Seminar Series continues with Dr. Matthew Clair, Assistant Professor in the Department of Sociology and (by courtesy) the Law School at Stanford University.Dr. Clair’s talk, titled “Recognizing and Responding to Racism: Lessons for Health and Medicine," explores social inequities in medicine.
Join Ruth Lehmann, Director, Whitehead Institute, and Jill Shah, President, Shah Family Foundation, as they discuss philanthropy as a catalyst for government innovation in the areas of nutrition, education, and economic support.
This webinar from November 30, 2021, featuring Whitehead Institute Member Robert Weinberg and moderated why Whitehead Valhalla Fellow Tobiloba Oni, focuses on the challenging question: How do cancer cells arising in one tissue learn to adapt and proliferate in tissues to which they have spread through metastasis?
A conversation featuring Ruth Lehmann and Kevin B. Churchwell, MD, the President and Chief Executive Officer of Boston Children’s Hospital and a member of the Whitehead Institute Board of Directors.
Whitehead Institute director Ruth Lehmann spoke virtually on October 19, 2021 with Linda Henry, CEO, Boston Globe Media Partners, and Rick Berke, Co-Founder & Executive Editor, STAT, on the importance of accurate science communication.
We continue the Institute’s Diversity, Equity and Inclusion seminar series with Dr. Marcelo Suárez-Orozco, Chancellor of the University of Massachusetts Boston.
Whitehead Institute Member Olivia Corradin and her lab are studying the genetics underlying opioid overdose. In this webinar, she describes the changes they have identified in the brain and how these changes converge on genes critical to the disorder.
In this webinar, Whitehead Fellow Tobi Oni outlines the general principles of anti-tumor immune responses and discusses his lab's strategies to unleash an immune attack against pancreatic cancer.
The challenges presented by climate change are wide-ranging — and so must be science's response. In this Director’s Dialogue, which took place on May 4, 2021, three Whitehead Institute scientists, Jing-Ke Weng, Mary Gehring and Jonathan Weissman, speak with Institute Director Ruth Lehmann about exciting opportunities for leveraging fundamental biological research to create biotechnologies that address some of climate change's vexing effects.
In this webinar, which took place April 8, 2021, Whitehead Institute Member Yukiko Yamashita highlights ways in which fundamental research brings novel biological processes to light, and introduces her lab’s latest discoveries on the function of satellite DNA, which has long been regarded as “genomic junk.”
On March 22, Whitehead Institute Director Ruth Lehmann spoke with Moderna chairman and founder and CEO of life sciences venture capital company Flagship Pioneering Noubar Afeyan about the race to create a COVID-19 vaccine, the importance of immigrants in the US, and how to find and foster path-breaking ideas.
On February 25, 2021, Whitehead Institute Director Ruth Lehmann discussed the implications of this new age MIT President Emerita Susan Hockfield, in the first installment of our new series, Director's Dialogues. Hockfield, who was the first life scientist to lead MIT, is the author of the 2019 book, “The Age of Living Machines: How Biology Will Build the Next Technology Revolution.”
In this presentation and discussion moderated by Whitehead Institute Member Pulin Li, hear what Whitehead Fellows Silvia Rouskin and Kipp Weiskopf are learning about SARS-CoV-2 — and how their research may aid in the fight against dangerous coronaviruses, now and well into the future.
In this talk from May 27, 2021, Whitehead Institute Director Ruth Lehmann talks to biomedical researcher, MIT professor, and biotech entrepreneur Sangeeta Bhatia. Bhatia leverages ‘tiny technologies’ of miniaturization to yield inventions such as human microlivers that model human drug metabolism and liver disease, as well as responsive nanoparticles and nanoporous materials that can be engineered to diagnose, study, and treat a variety of diseases, including cancer.